open access

Vol 70, No 6 (2019)
Clinical vignette
Published online: 2019-11-19
Submitted: 2019-06-16
Accepted: 2019-07-19
Get Citation

Liver transplantation as an option of treatment for a giant primary hepatic neuroendocrine tumour

Grzegorz Oczkowicz, Artur Caban, Anna Zemczak, Jolanta Kunikowska, Beata Kos-Kudła, Robert Król
DOI: 10.5603/EP.a2019.0052
·
Pubmed: 31909457
·
Endokrynologia Polska 2019;70(6):520-521.

open access

Vol 70, No 6 (2019)
Clinical Vignette
Published online: 2019-11-19
Submitted: 2019-06-16
Accepted: 2019-07-19

Abstract

There are no clear guidelines for the treatment of hepatic neuroendocrine tumours. Surgical resections — though rarely radical — seem to be the treatment of choice. Thermoablation, chemoembolisation, or cytoreductive surgery of hepatic focal lesions are often recommended.

Pharmacological treatment is based on somatostatin analogues. Liver transplantation is available for a strictly selected group of patients with hepatic neuroendocrine tumours [5]. In the case described above, there were a number of factors that affected the decision about eligibility: first of all — very slow growth of the tumour, its size, and typical multifocality, which made it impossible to perform resection, lack of neoplastic focus outside the liver, and low Ki-67 proliferation index of ≤ 2%. The surgical risk was escalated due to the giant tumour mass and the laparotomy, which was performed twice. 

Abstract

There are no clear guidelines for the treatment of hepatic neuroendocrine tumours. Surgical resections — though rarely radical — seem to be the treatment of choice. Thermoablation, chemoembolisation, or cytoreductive surgery of hepatic focal lesions are often recommended.

Pharmacological treatment is based on somatostatin analogues. Liver transplantation is available for a strictly selected group of patients with hepatic neuroendocrine tumours [5]. In the case described above, there were a number of factors that affected the decision about eligibility: first of all — very slow growth of the tumour, its size, and typical multifocality, which made it impossible to perform resection, lack of neoplastic focus outside the liver, and low Ki-67 proliferation index of ≤ 2%. The surgical risk was escalated due to the giant tumour mass and the laparotomy, which was performed twice. 

Get Citation

Keywords

neuroendocrine tumour; liver transplantation

About this article
Title

Liver transplantation as an option of treatment for a giant primary hepatic neuroendocrine tumour

Journal

Endokrynologia Polska

Issue

Vol 70, No 6 (2019)

Article type

Clinical vignette

Pages

520-521

Published online

2019-11-19

DOI

10.5603/EP.a2019.0052

Pubmed

31909457

Bibliographic record

Endokrynologia Polska 2019;70(6):520-521.

Keywords

neuroendocrine tumour
liver transplantation

Authors

Grzegorz Oczkowicz
Artur Caban
Anna Zemczak
Jolanta Kunikowska
Beata Kos-Kudła
Robert Król

References (5)
  1. Scheuer P. Tumors of the Liver and Intrahepatic Bile Ducts. J Clin Pathol. 1990; 43(9): 786–786.
  2. Song JE, Kim BS, Lee CH. Primary hepatic neuroendocrine tumor: A case report and literature review. World J Clin Cases. 2016; 4(8): 243–247.
  3. Cha DIk, Kang TW, Jang KM, et al. Hepatic neuroendocrine tumors: gadoxetic acid-enhanced magnetic resonance imaging findings with an emphasis on differentiation between primary and secondary tumors. Abdom Radiol (NY). 2018; 43(12): 3331–3339.
  4. Zhao ZM, Wang J, Ugwuowo UC, et al. Primary hepatic neuroendocrine carcinoma: report of two cases and literature review. BMC Clin Pathol. 2018; 18: 3.
  5. Bonaccorsi-Riani E, Apestegui C, Jouret-Mourin A, et al. Liver transplantation and neuroendocrine tumors: lessons from a single centre experience and from the literature review. Transpl Int. 2010; 23(7): 668–678.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl